| |
Tumour
|
Muscle
|
---|
Patient
|
Clinical
|
Baseline
|
After 8–10# CRT
|
% Changes
|
Baseline
|
After 8–10# CRT
|
% changes
|
---|
Number
|
Response
|
F
|
Ka
|
F
|
Ka
|
F
|
Ka
|
F
|
Ka
|
F
|
Ka
|
F
|
Ka
|
---|
P1
|
Poor
|
0.588
|
1.380
|
0.294
|
1.188
|
−50
|
−14
|
0.144
|
0.018
|
0.570
|
0.864
|
296
|
4700
|
P2
|
Good
|
1.428
|
1.578
|
2.472
|
0.702
|
73
|
−56
|
0.102
|
0.042
|
0.672
|
1.434
|
559
|
3314
|
P3
|
Poor
|
3.198
|
0.912
|
2.484
|
0.696
|
−22
|
−24
|
0.120
|
0.018
|
0.600
|
0.360
|
400
|
1900
|
P4
|
Poor
|
4.410
|
0.630
|
3.132
|
0.702
|
−29
|
11
|
0.126
|
0.024
|
0.600
|
0.360
|
376
|
1400
|
P5
|
Good
|
6.702
|
0.924
|
4.380
|
0.720
|
−35
|
−22
|
0.138
|
0.006
|
0.600
|
0.360
|
335
|
5900
|
P6
|
Poor
|
6.702
|
0.924
|
–
|
–
|
–
|
–
|
0.600
|
0.444
|
–
|
–
|
–
|
–
|
P7
|
Good
|
3.942
|
0.924
|
4.656
|
0.618
|
18
|
−33
|
0.174
|
0
|
0.054
|
1.116
|
−69
|
n.d.
|
P8
|
Poor
|
4.368
|
0.870
|
0.750
|
0.312
|
−83
|
−64
|
0.078
|
4.806
|
0.348
|
2.058
|
346
|
−57
|
P9
|
Poor
|
4.248
|
0.714
|
0.756
|
0.096
|
−82
|
−87
|
0.084
|
0.036
|
0.480
|
1.056
|
471
|
2833
|
P10
|
Good
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
P11
|
Good
|
2.526
|
0.762
|
6.192
|
0.720
|
145
|
−6
|
0.114
|
0.006
|
0.600
|
0.366
|
426
|
6000
|
Median
| |
4.100
|
0.920
|
2.480
|
0.700
|
−28.980
|
−23.680
|
0.120
|
0.020
|
0.600
|
0.860
|
376.190
|
3073.810
|
IQR
| |
1.710
|
0.140
|
3.620
|
0.100
|
68.110
|
41.600
|
0.040
|
0.030
|
0.120
|
0.760
|
91.530
|
3225.000
|
-
[
18
F]FMISO [18F]fluoromisonidazole, % percentage, n.d. not defined, IQR interquartile range. PET positron emission tomography, min minute